GlassScriptPhysician profile
Lisa A Lamberti
NPI 1992794192
$7,665.62
in general payments reported to CMS, 2019-2025
31 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $905 · 2022: $1,622 · 2023: $1,634 · 2024: $1,796 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,125 · Education: $13.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,124.55 |
| Education | $13.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,828.40 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,071.43 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $868.88 | 2021-2025 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $774.85 | 2021-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $500.35 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $311.00 | 2024-2025 | Zenpep |
| Pfizer INC. | $308.09 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $293.96 | 2021-2025 | Entyvio, Eohilia, Gattex |
| E.R. Squibb & Sons, L.L.C. | $249.66 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $204.41 | 2021-2024 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $154.73 | 2021-2024 | |
| Ardelyx, INC. | $144.41 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $126.71 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $125.07 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $96.49 | 2021-2023 | Sutab, Suflave |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $68.31 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $65.56 | 2021-2025 | |
| Madrigal Pharmaceuticals | $60.77 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $59.00 | 2021-2024 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $47.61 | 2022-2024 | Kristalose |
| Exact Sciences Corporation | $39.75 | 2023-2025 | Cologuard Collection Kit |
| Biocon Biologics INC | $38.96 | 2025 | Yesintek |
| Ethicon US, LLC | $38.62 | 2021 | |
| Novo Nordisk INC | $36.94 | 2025 | Wegovy |
| Blueprint Medicines Corporation | $35.17 | 2024-2025 | Ayvakit |
| Qol Medical, LLC | $28.87 | 2021 | |
| W. L. Gore & Associates, INC. | $19.17 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.82 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $17.71 | 2023 | |
| Organon LLC | $16.36 | 2021 | |
| Genzyme Corporation | $15.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Lamberti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.